Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01471782
What this trial is testing

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH 93
Post-approval studies (Phase 4)Looking for participantsNCT06930573
What this trial is testing

AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC
The First Affiliated Hospital of Zhengzhou University 30
Not applicableNot Yet RecruitingNCT06888856
What this trial is testing

Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients

Who this might be right for
Multiple Myeloma (MM)
Tel-Aviv Sourasky Medical Center 200
Early research (Phase 1)Ended earlyNCT03038230
What this trial is testing

MCLA-117 in Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous LeukemiaAcute Myeloid Leukemia
Merus B.V. 80
Testing effectiveness (Phase 2)Looking for participantsNCT06787612
What this trial is testing

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Regeneron Pharmaceuticals 297
Early research (Phase 1)Study completedNCT00244946
What this trial is testing

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Barbara Ann Karmanos Cancer Institute 15
Large-scale testing (Phase 3)Looking for participantsNCT07393282
What this trial is testing

Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Who this might be right for
High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals 270
Large-scale testing (Phase 3)Looking for participantsNCT06980480
What this trial is testing

Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Who this might be right for
Multiple MyelomaSecondary Immunodeficiency
Takeda 183
Testing effectiveness (Phase 2)WithdrawnNCT00149019
What this trial is testing

Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.

Who this might be right for
Metastatic Solid Tumors
Hadassah Medical Organization 12
Early research (Phase 1)Active Not RecruitingNCT03145181
What this trial is testing

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 302
Large-scale testing (Phase 3)Looking for participantsNCT07648264
What this trial is testing

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Who this might be right for
Secondary Immune Deficiency
CSL Behring 63
Early research (Phase 1)Looking for participantsNCT07439263
What this trial is testing

Single Ascending Dose Study of HB2198 in Healthy Participants

Who this might be right for
Healthy Volunteer
Hinge Bio 32
Testing effectiveness (Phase 2)Ended earlyNCT05117242
What this trial is testing

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Genmab 125
Early research (Phase 1)Ended earlyNCT03661424
What this trial is testing

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Who this might be right for
Breast Cancer FemaleLeptomeningeal Metastases
University of Virginia 3
Early research (Phase 1)Active Not RecruitingNCT05890963
What this trial is testing

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults

Who this might be right for
HIV-1-infection
David Ho 20
Testing effectiveness (Phase 2)Study completedNCT02620865
What this trial is testing

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage III Pancreatic Cancer+1 more
Barbara Ann Karmanos Cancer Institute 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07561645
What this trial is testing

A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

Who this might be right for
Large Cell Neuroendocrine Carcinoma of the Lung
Technische Universität Dresden 75
Early research (Phase 1)Active Not RecruitingNCT06723964
What this trial is testing

AP505 Injection in Patients With Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumors
AP Biosciences Inc. 35
Testing effectiveness (Phase 2)Looking for participantsNCT06993675
What this trial is testing

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Who this might be right for
Multiple Myeloma
Noffar Bar 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07612787
What this trial is testing

Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

Who this might be right for
Myeloma Multiple
Centre Hospitalier Universitaire de Saint Etienne 44
Next Page